Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
Heading into 2026, the landscape could continue to reward investors willing to take on a bit of risk. The benefit of lower interest rates and improved funding conditions may drive further investment in biotechs, particularly in companies with clear paths toward commercial success. Many of the standout biotech stocks to watch in 2026 have tangible catalysts to drive growth.
